Biosimilars: Bringing patients into the conversation
Published in eyeforpharma January 2017 by Mariel Metcalfe
In a recent white paper, we explored the impact that biosimilars are having and likely to have on the rising cost of RA treatment. We looked at physician attitudes to biosimilars and the challenges manufacturers face in gaining widespread acceptance.
Research Partnership makes annual donation to Forever Angels
We are delighted to announce that Research Partnership has made a seasonal donation of US$5,000 to our chosen charity, Forever Angels. Fundraising efforts by our employees throughout the year contributed to this total.
Forever Angels is committed to providing support to young children in Tanzania. This wonderful charity provides nutrition and loving, holistic care to needy children, helping to preserve the family wherever possible. Their two main projects are Forever Angels Baby Home and Maisha Matters - a community outreach program which provides orphan babies with life-saving formula milk in their own homes and helps their relatives set up a sustainable business so they can support their families into the future.
A bitter pill?
The ideal route of admin isn’t clear cut in the global marketplace
A key feature of any pharmaceutical product is its route of administration; the path through which the drug is taken into the body. This may be oral, injectable, transdermal or inhaled. Differences in route of admin can be critical points of differentiation for new pharmaceutical products, especially in crowded markets where multiple options are available. When conducting interviews with healthcare professionals, we commonly find that route of admin is often one of the first features they take into account (after efficacy and safety) when reviewing product profiles, and getting it right is fundamental to a product’s eventual uptake and market share. However the perceived benefits and drawbacks of different routes of administration can be more complicated than one might think. Market nuances can have far-reaching implications for drug formulation and device design.
ACR conference 2016
We were delighted to be chosen to present two posters at this year’s ACR conference in Washington on November 11-16. The posters, which are entitled, ‘A Real World View of Rheumatoid Arthritis Patients Treated with Advanced Therapies’ and ‘Patient Adherence with Biologic Therapy in RA’ are authored by Research Director Laurent Chanroux.
Understanding the chronic disease patient journey in emerging markets
In this paper, we explore the chronic disease patient journey in emerging markets and provide you with the insights you require to identify the key inflection points in these rapidly changing and diverse regions.
With growing urban populations and increasing purchasing power, emerging markets remain an attractive prospect for growth. A high proportion of the urban emerging market population already suffers from chronic diseases and prevalence is set to further increase as lifestyles become closer to those in the West. The chronic disease patient is a critical stakeholder in emerging markets because they often have to pay for their healthcare out of pocket. Moreover, these markets often don’t have formal primary care systems, so the patient is the only constant in the journey. Understanding their journey is critical in order to best leverage these potential new markets.